SCHEMBL19355262

SCHEMBL19355262

CC(CCNc1cc(-c2ccc3ccncc3c2)ncn1)c1ccnc2c1OCCO2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 8/20 0.36
CYP3A4 P08684 8/20 0.36
CLK4 Q9HAZ1 8/20 0.36
HSD17B10 Q99714 6/20 0.36
ALDH1A1 P00352 5/20 0.36
ALOX15 P16050 4/20 0.36
CYP2D6 P10635 4/20 0.36
TP53 P04637 3/20 0.36
CYP2C19 P33261 3/20 0.36
KDM4E B2RXH2 2/20 0.36
HPGD P15428 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MAPK1 P28482 2/20 0.36
DYRK1A Q13627 2/20 0.36
CYP2C9 P11712 1/20 0.36
CLK1 P49759 1/20 0.36
PRKDC P78527 2/20 0.33
FAAH O00519 2/20 0.33
ITGB2 P05107 1/20 0.33
ICAM1 P05362 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17634596 0.92 PRKDC (0.39) CYP1A2CYP3A4CLK4HSD17B10ALDH1A1
SCHEMBL17634598 0.90 PRKDC (0.39) CYP1A2CYP3A4CLK4HSD17B10ALDH1A1
SCHEMBL19905131 0.84 CYP1A2 (0.41) CYP1A2CYP3A4CLK4HSD17B10ALDH1A1
SCHEMBL19355480 0.80 PRKDC (0.35) CYP1A2CYP3A4CLK4HSD17B10ALDH1A1
SCHEMBL19355263 0.80 CLK4 (0.41) CYP1A2CYP3A4CLK4HSD17B10ALDH1A1
SCHEMBL19355114 0.80 PRKDC (0.35) CYP1A2CYP3A4CLK4HSD17B10ALDH1A1
SCHEMBL20373196 0.79 PRKDC (0.38) CYP1A2CYP3A4CLK4HSD17B10ALDH1A1
SCHEMBL17634607 0.79 PRKDC (0.38) CYP1A2CYP3A4CLK4HSD17B10ALDH1A1
SCHEMBL19355401 0.78 PRMT5 (0.31) PRKDC
SCHEMBL17634599 0.78 TRPV1 (0.40) CYP1A2CYP3A4CLK4HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180193341-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2018-07-12 US disclosed
US-20170258789-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170258789-A1 DNA-PK INHIBITORS POLK, DTYMK, DCK CYP1A2 2215/4885CYP3A4 1759/4885CLK4 383/4885
US-20180193341-A1 DNA-PK INHIBITORS POLK, DTYMK, DCK CYP1A2 2215/4885CYP3A4 1759/4885CLK4 383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.